Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy (SABAL)
This study has been completed.
Information provided by (Responsible Party):
Karin Dam Petersen, Aalborg University
First received: December 3, 2011
Last updated: December 5, 2011
Last verified: December 2011
Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)
Quality of Life
Effects of Immunotherapy
||Observational Model: Case Control
Time Perspective: Prospective
||Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||November 2009 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||16 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
The intervention group consisted of 254 patients receiving subcutaneous allergen specific immunotherapy (SCIT) with grass pollen and/or house dust mite extracts. The control group consisted of 317 patients with grass pollen and/or house dust mite allergy, who were not receiving SCIT.
- Adults (> 16 years) and allergic to grass pollen and/or house dust mites.
- Allergic patients who had been immunotherapy treated before.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01486498
||Karin D Petersen, PhD
No publications provided
||Karin Dam Petersen, Associate Professor, Aalborg University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 3, 2011
||December 5, 2011
||Denmark: Danish Dataprotection Agency
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 14, 2014
Respiratory Tract Diseases
Lung Diseases, Obstructive
Immune System Diseases